Navigation Links
Hopkins AIDS experts issue warning about global efforts to provide drug therapies

Johns Hopkins infectious disease specialists who have spent more than two decades leading efforts to combat HIV and AIDS worldwide are warning that limited international relief supplies of antiretroviral therapies currently being distributed in Africa, Asia and the Caribbean will not get to those who can least afford to pay for them.

In an article appearing in the American Journal of Public Health online June 28, infectious disease specialist Jonathan Zenilman, M.D., a professor at The Johns Hopkins University School of Medicine, reports that poorer people have been left out in the past due to insufficient local planning, and that donors and developing countries should learn from these mistakes as the number of people requiring therapy continues to grow.

"Local health officials are faced with the unenviable and difficult task of having to decide who will get therapy and live, and who will have to do without and possibly die," he says. "But this dilemma is unavoidable because supply will fall far short of demand, despite the generous nature and growing scope of aid efforts."

While President Bush's 2003 Emergency Plan for AIDS Relief is spending more than $600 million on antiretroviral therapies for 2 million people, demand in the developing world is even greater and steadily growing, with at least 6.5 million people in need of drug therapy and only 15 percent receiving any. And, Zenilman notes, treatment for HIV is a lifelong need for infected people.

"Even if the president's plan was successful and included with the Global Fund to Fight AIDS, Tuberculosis and Malaria, which calls for providing treatment to 3 million people by 2005, these efforts would only reach half of those in need," says Zenilman, senior author of the journal article.

"Though more people in developing countries are receiving therapy, growing from 400,000 in June 2004 to 700,000 in December 2004, it still amounts to only 4 percent of infected people in India,
'"/>

Source:Johns Hopkins Medical Institutions


Page: 1 2 3 4

Related biology news :

1. Hopkins scientists uncover tags that force proteins to cell surface
2. Johns Hopkins flu expert calls for mandatory vaccination of health care workers
3. Whole-genome study at Johns Hopkins reveals a new gene associated with abnormal heart rhythm
4. Hopkins researchers discover genetic switch that turns off an oxygen-poor cells combustion engine
5. Hopkins study suggests commercially available antibiotic may help fight dementia in HIV patients
6. Johns Hopkins lab scientists tame overactive CF protein
7. Hopkins researchers develop new tool to watch real-time chemical activity in cells
8. Hopkins scientists show hallucinogen in mushrooms creates universal mystical experience
9. Hopkins researchers discover how brain protein might control memory
10. Hopkins scientists link immune response to ghost parasites and severely congested sinuses
11. South Americas vast pantanal wetland may become next everglades, UNU experts warn

Post Your Comments:
(Date:11/20/2009)...possess an ingenious mechanism for preventing oxyg...his is the new finding of a team of biologists tha...esearch institute in Flanders, Belgium, connected ...made this discovery by modifying the DNA of the in... this model organism, they have uncovered the exis...
(Date:11/20/2009)...COPD), a respiratory disease commonly known as chr...g cause of death worldwide. 600 million people li...d any real treatment or cure, Grace Parraga of Rob...rn Ontario in London, Canada, is using various ima...se. , Parraga is a scientist in the Imaging ...
(Date:11/19/2009)...al with an unwieldy name: 4-hydroxybutyrate (4-HB)...te-rape drug. , Now, a team of Ohio and Michiga...-HB is metabolized by the body. "This is new and i...fessor and chair of biological sciences at Michiga...earch team. "It may provide new clues on how to c...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2SHPS Receives Re Accreditation from URAC for Multiple Health Management Programs 48486 1SHPS Receives Re Accreditation from URAC for Multiple Health Management Programs 48486 2Studies Report More Harmful Effects From BPA 48481 1Studies Report More Harmful Effects From BPA 48481 2Studies Report More Harmful Effects From BPA 48481 3Preliminary report on antidepressants published 48477 1Preliminary report on antidepressants published 48477 2
... is available in German . , The coal tit appear...n stay together for their whole lives. That,s only...op ten two-timers worldwide. That is what research...r this they have taken genetic fingerprints from m...this way they were able to identify the biological...
...in her lab showed that mate (mah tā) tea drin... activity of an enzyme that promotes HDL (good) ch...iversity of Illinois scientist Elvira de Mejia hea...d taken medicinally for centuries. , She returned...rs of La Universidad Nacional de Misiones (UNaM) t...
.... By most measures of an academic medical centers...hip, fiscal year 2007 was a banner year for Oregon...disclosed 132 inventions, more than in any previou...e number in 2000. , Five new startup companies ... the year, bringing the total to 33 since 2000 and...
Other Biology News:Age increases chance of success as two-timer 2Age increases chance of success as two-timer 3More on mate tea: lower cholesterol and an international agreement 2OHSU turns innovations into commercial opportunities at record pace 2OHSU turns innovations into commercial opportunities at record pace 3OHSU turns innovations into commercial opportunities at record pace 4OHSU turns innovations into commercial opportunities at record pace 5
(Date:11/20/2009)...0 Veridiam (www.veridiam.com) won ...any category at the 2009 Workplace Excellence Awar...ety for Human Resources Management and recognize i...s. ,, Veridiam was one of nine winners, selecte... honored at the recent awards ceremony. San Diego-...
(Date:11/20/2009)...TTLER TOLEDO recently announced that a free webina...Using At-Line Particle Characterization”, wi...nar, the application of in situ particle character...d optimize a series of roller compaction runs whil...mpaction forces. , (PRWEB...
(Date:11/19/2009)...ov. 19 Dr. Mate Hidvegi, inventor ...o a press release issued on November 17 by Biropha...king false and self-serving statements about its U...dvegi stated from his office in Budapest, Hungary:...mar does not apply to AveULTRA, www.aveultra.com...
(Date:11/19/2009)...ermany, November 19 MONITORING FOR... 16th, 2009 Flibanserin in the,indication treatmen...n,s,disease for orphan drug status designation wit...nduced dyskinesia is a complication of the mainsta...burden to some of those,affected, since it may be ...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...TCH (Taxotere, Carboplatin, Herceptin) showed a si...DFS) and Overall Survival (OS), compared to AC-T,(...axel) and a 5-fold lower, cardiotoxicity compare... adjuvant therapy for HER2-positive E...tional,Research Group (CIRG), a division of TRIO (...
...RICHMOND, Calif., May 29 Sangamo BioSciences,Inc....hier, Sangamo,s,president and CEO, will provide an...at 1:40 p.m. (ET) on Friday, June 6, 2008, at the ... San Francisco., The presentation will be webcast...o BioSciences website in the Investor Relations se...
...SWARTZ CREEK, Mich., May 29 Diplomat Specialty,Ph...isease management (DM),and drug therapy management...cy was one of 3 sponsors of the National Managed C...Texas. This forum brought 30 industry,executives f...together to,review and improve on the current offe...
Other Biology Technology:First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA 2First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA 3First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA 4Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference 2Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board 2
...and miRNA Isolation Traditional mRNA isolation pr... and can result in the loss of substantial amounts...t purifies all RNA species (including small RNAs),...chment procedure included in the mirVana miRNA Iso...
...AD: 5B15-5B-11E. Immunogen: Synthetic peptide der...rotein. Specificity: Specific for the internal r...entifies the target band at ~590 kDa. Reactivity:...d media from primary tracheobranchial epithelial c...
GIBCO Keratinocyte-SFM (1X) liquid from Invitrogen
Rabbit Anti-LSD1 / BHC110 Antibody, Unconjugated from Upstate
Biology Products: